Best products for dryness

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.

Controlled study of topical lactic acid on human skin: lactic acid increased stratum corneum ceramide content and improved epidermal firmness, thickness, and smoothness; effects were concentration- and pH-dependent (higher free-acid/low-pH produced greater epidermal response). Supports lactic acid as a barrier-supporting humectant AHA.

Randomized controlled trial (26 weeks): Lactic arm of three AHA comparison demonstrating dermal remodeling.

Randomized controlled trial: Head to head glycolic vs lactic at equivalent concentration.

Randomized controlled trial (n=30): Lactic vs Jessner head to head equally effective.

Randomized controlled trial (n=20): Pivotal lactic peel evidence for melasma in fitzpatrick IV dominant population.

Clinical study: Establishes lactic acid for ichthyosis and keratosis pilaris treatment.

In-vitro/mechanistic study: Unique lactic barrier building mechanism via ceramide synthesis.

Topical lactic acid (5-12%) uniquely stimulated ceramide synthesis in human stratum corneum, increasing ceramide levels by approximately 25% after 4 weeks; this effect was not observed with glycolic acid, malic acid, or citric acid at equivalent concentrations; mechanism supports use for barrier-impaired skin

Review: Modern review of basic emollient components for AD xerosis including lactic acid at low concentrations as humectant component.

Systematic review: Breastfeeding nipple pain evidence consolidation including panthenol as lanolin alternative.